TY  - JOUR
AU  - Forbes, Lisa R
AU  - Vogel, Tiphanie P
AU  - Cooper, Megan A
AU  - Castro-Wagner, Johana
AU  - Schussler, Edith
AU  - Weinacht, Katja G
AU  - Plant, Ashley S
AU  - Su, Helen C
AU  - Allenspach, Eric J
AU  - Slatter, Mary
AU  - Abinun, Mario
AU  - Lilic, Desa
AU  - Cunningham-Rundles, Charlotte
AU  - Eckstein, Olive
AU  - Olbrich, Peter
AU  - Guillerman, R Paul
AU  - Patel, Niraj C
AU  - Demirdag, Yesim Y
AU  - Zerbe, Christa
AU  - Freeman, Alexandra F
AU  - Holland, Steven M
AU  - Szabolcs, Paul
AU  - Gennery, Andrew
AU  - Torgerson, Troy R
AU  - Milner, Joshua D
AU  - Leiding, Jennifer W
PY  - 2018
DO  - 10.1016/j.jaci.2018.07.020
UR  - http://hdl.handle.net/10668/12815
T2  - The Journal of allergy and clinical immunology
AB  - Treatment of the autoimmune and immune-dysregulatory features of patients with STAT1 GOF or STAT3 GOF disease remains challenging. Jakinibs have been used to treat the severe immune-dysregulation in patients with either STAT1 GOF or STAT3 GOF mutations.
LA  - en
KW  - Adolescent
KW  - Adult
KW  - Child
KW  - Female
KW  - Gain of Function Mutation
KW  - Humans
KW  - Immunologic Deficiency Syndromes
KW  - Janus Kinases
KW  - Male
KW  - Nitriles
KW  - Piperidines
KW  - Protein Kinase Inhibitors
KW  - Pyrazoles
KW  - Pyrimidines
KW  - Pyrroles
KW  - STAT1 Transcription Factor
KW  - STAT3 Transcription Factor
KW  - Treatment Outcome
TI  - Jakinibs for the treatment of immune dysregulation in patients with gain-of-function signal transducer and activator of transcription 1 (STAT1) or STAT3 mutations.
TY  - research article
VL  - 142
ER  -